Sun Sep 08 00:28:08 UTC 2024: – The Ministry of Health and Family Welfare has approved the use of a new drug called BPaLM for the treatment of Multi Drug Resistant Tuberculosis (MDR-TB) under the National Tuberculosis Elimination Program (NTEP).
– The drug includes a new anti-TB drug called Pretomanid, along with Bedaquiline, Linezolid and Moxifloxacin, and has been approved for use in India by the Central Drugs Standard Control Organization.
– The new drug combination is more effective, safer and faster-acting than previous MDR-TB treatments, with the potential to cure drug-resistant TB in just six months.
– The drug is expected to benefit around 75,000 drug-resistant TB patients in India, reducing the time and cost of treatment significantly.
– The Health Department has conducted thorough evaluations and consultations to ensure the safety and cost-effectiveness of the new drug for MDR-TB treatment, with the aim of achieving the national goal of eliminating TB in the country.

Read More